ID   Y-MESO-14/hPDPN
AC   CVCL_D2U3
DR   Wikidata; Q127384730
RX   PubMed=25080943;
RX   PubMed=28387591;
CC   Population: Japanese.
CC   Sequence variation: Gene deletion; HGNC; HGNC:6515; LATS2; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:950; BAP1; Simple; p.Lys116Glyfs*5 (c.349_359del11); Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7773; NF2; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000457921; Zygosity=Unspecified (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:29602; PDPN.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
DI   NCIt; C45665; Pleural biphasic mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5179 ! Y-MESO-14
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 30-01-24; Last updated: 19-12-24; Version: 3
//
RX   PubMed=25080943; DOI=10.1038/srep05924; PMCID=PMC4118152;
RA   Kato Y., Kaneko M.K.;
RT   "A cancer-specific monoclonal antibody recognizes the aberrantly
RT   glycosylated podoplanin.";
RL   Sci. Rep. 4:5924-5924(2014).
//
RX   PubMed=28387591; DOI=10.1089/mab.2017.0001;
RA   Yamada S., Ogasawara S., Kaneko M.K., Kato Y.;
RT   "LpMab-23: a cancer-specific monoclonal antibody against human
RT   podoplanin.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 36:72-76(2017).
//